Effect of royal jelly in treatment of stroke

Phase 3

• Conditions: Ischemic stroke.; Cerebellar stroke syndrome; G46.4

• Registration Number: IRCT20180818040827N4
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Confirmed diagnosis of ischemic stroke by a neurologist
NIHSS score of 5-20
An absence of previous stroke or or MRS score of = 1 for those with previous stroke
Ischemic stroke of non-brain stem area
age of 45-80
Not following specific dietary regimen in previous 3 months
Not taking multivitamins and antioxidant supplements in the previous 3 months
Non pregnant and lactating women
No other diseases such as acute kidney, liver, heart, other neurological diseases, malignancies, no asthma, allergies and dermatitis
Not suffering from mental retardation (mental disabilities)
Not taking drugs that interfere with Royal Jelly supplementation (warfarin)
Lack of sensitivity and allergy to honey and its products

Exclusion Criteria

Unwillingness to continue the study for any reason
Adherence of less than 80% to the intervention (taking less than 80% of Royal Jelly supplement that should be taken during the 12 weeks of the intervention will be considered low adherence)
Recurrence of stroke
Death
Use of antioxidant and multivitamin supplements during the study
Prescription of warfarin during the study
Gastrointestinal side effects or allergies caused by taking Royal Jelly supplement
Diagnosis of other diseases such as kidney, autoimmune and malignancies during the study

Study & Design

• Study Type: interventional
• Study Design: Not specified